News

€17m for pan-European PPP
Enlarge image

BusinessItalySwitzerland

€17m for pan-European PPP

29.10.2012 - It is a significant upgrade for Italian basic research: British-Swiss Shire collaborates with Telethon Foundation on rare disease drugs.

It is a company first for British Shire Pharmaceuticals plc. Despite having had strong ties with academia for a while, the pharma firm has also finally partnered up in a public-private partnership (PPP) with an academic institution for the first time. Last week Swiss Shire Human Genetic Therapies – Shire’s stock corporation from Nyons – and Italian Telethon Foundation entered a long-term collaboration in discovering new medicines against rare diseases. In particular, Shire will spend over the next five years €17m on research on 13 mainly undisclosed indications. The only thing known is that a number of different lysosomal storage disorders and neurodegenerative disorders are among them. With this long-term collaboration, the British hope to boost their early stage pipeline. The terms for Shire picking up a ripening project and eventually bringing it through mid and late clinical stages are still under discussion.

Telethon general manager Francesca Pasinelli underscored the importance of the deal for her foundation: „For a not-for-profit organisation like ours, this alliance represents an opportunity to fulfil the promise made to patients and donors who have been supporting us.“ Most of the research will be carried out at the Telethon Institute of Genetics and Medicine (TIGEM) in Naples. The institute’s research strength lies in gene therapeutics.

Earlier this year Shire launched another early-stage programme together with zinc-finger-technology torchbearer Sangamo Bioscience (tackling haemophilia). While Shire now enters virgin soil with a public-private partnership, Telethon already has some experience in this respect. Since 2010 the foundation – together with GlaxoSmithKline – has been developing a gene therapy for the devastating immune deficiency ADA-SCID.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/eur17m-for-pan-european-ppp.html

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

BusinessPolandUK

01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • METABOLIC EXPLORER (F)2.26 EUR17.10%
  • CERENIS THERAPEUTICS HOLDING SA (F)8.09 EUR7.72%
  • MOLMED (I)0.42 EUR7.69%

FLOP

  • PHOTOCURE (N)46.40 NOK-8.12%
  • VERNALIS (UK)43.00 GBP-4.44%
  • E-THERAPEUTICS (UK)11.75 GBP-4.08%

TOP

  • DIAMYD MEDICAL -B- (S)7.05 SEK67.9%
  • KARO BIO (S)38.30 SEK33.4%
  • NEWRON (CH)20.65 CHF24.8%

FLOP

  • BIONOR PHARMA (N)0.47 NOK-23.0%
  • NOVOZYMES (DK)284.10 DKK-14.4%
  • WILEX (D)1.53 EUR-12.6%

TOP

  • KARO BIO (S)38.30 SEK2453.3%
  • NICOX (F)10.33 EUR470.7%
  • SAREUM HOLDINGS (UK)0.74 GBP252.4%

FLOP

  • BB BIOTECH (D)46.45 EUR-80.4%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.30 EUR-70.4%

No liability assumed, Date: 23.08.2016